TOP2A amplification predicts improved efficacy to epirubicin in patients with breast cancer [20, 21] and thus could be an alternative option to irinotecan-based therapy in patients with CRC and TOP2A amplification who relapsed on oxaliplatin containing chemotherapy. Here, TOP2A is linked to breast cancer.